384 results about "Effective drug concentration" patented technology

A composite medicine for treating solid tumor by locally putting it in the tumor is composed of the active anticancer components (Pt compound and its synergist choosen from taxol-type anticancer medicine, antineoplastic antibiotic and antimetabolitic medicine), and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).

A composite medicine for treating solid tumor by locally putting it in the tumor is composed of the active anticancer component (plant alkaloid and its symergist chosen from taxol-type anticancer medicine, antineoplastic antibiotic and antimetabolitic), and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).

A composite medicine for treating tumor by locally putting it in the tumor is composed of the active anticancer components (topoenzyme inhibitor and its symergist chosen from taxol-type anticancer medicnie, antineoplastic antibiotic and antimetabolitic medicine) and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).

Disclosed is an anti solid tumor medicine composition, which comprises medicinal adjuvant and DNA restoring enzyme inhibitor and/or Nitrosoureas anti-cancer drugs, wherein the DAN restoring enzyme inhibitor is selected from methoxamine, hydroxylamine and their analogues, which can effectively destroy the DNA restoring function in the tumor cells, and lower the survivability of tumor cell to Semustine anti-cancer drugs and their analogues, the medicinal adjuvant is biological compactable, degradable and absorbing macromolecular polymer, which can slowly release the DNA restoring enzyme inhibitor onto tumor partially during the degradation and absorption process, thus the whole body toxicity reaction is reduced appreciably , and the effective medicinal concentration can be sustained to the tumor partially. By dispensing the composition to the tumor partially, the whole body toxicity reaction of Nitrosoureas anti-cancer drugs and/or DNA restoring enzyme inhibitor can be lowered, selectively increase the tumor local medicinal concentration, and the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation can be improved.

An anticancer in vivo implant applied locally is prepared from the anticancer nitrosourea-type medicine, the anticancer synergist chosen from nitrogen mustard compound, mitotic inhibitor and antimetabolic anticancer medicine, and the biocompatible and biodegradable high-molecular polymer as medicinal additive.

The invention relates to a tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system, as well as a preparation method and application thereof. The tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system comprises mesoporous silica nano-particles, RGD polypeptide which is linked to the surfaces of the mesoporous silica nano-particles in a covalent manner and serves as a tumor vessel/tumor cell membrane targeting ligand, and a nuclear localization signal polypeptide sequence serving as a cell nucleus targeting ligand. Under the condition of intravenous injection, the drug-loaded system can be enriched in a tumor tissue by means of the targeting effect of the tumor vessel to reduce the uptake of normal tissues and reduce toxic and side effect, is capable of increasing the phagocytosis amount of tumor cells by means of the identification effect on the tumor cell membrane, and can be used for directly delivering anti-cancer drugs into a cell nucleus by means of the delivery performance of the cell nucleus to increase the concentration of effective drugs, so that an optimal treatment effect can be achieved.

The present invention relates to a slow-released preparation containing beta-lactamase inhibitor and cephalosporin. Said slow-released preparation can be made into antibiotic slow-released injection or slow-released implant preparation. Said injection is formed from slow-released microsphere and solvent, the slow-released microsphere contains slow-released auxiliary material and beta-lactamase inhibitor with antibacterial effective dose and cephalosporin, the solvent is special one containing suspension adjuvant of carboxymethyl cellulose sodium, etc. and its viscosity is 100 cp-3000 cp (20 deg.C-30 deg.C). The slow-released auxiliary material is selected from EVAc, polylactic acid copolymer, sebacic acid copolymer, albumin glue and gelatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application method. and can obtain obvious therapeutic effect for curing various infective diseases.

The invention discloses a merariveron sustained-release tablet and a preparation method thereof. The merariveron sustained-release tablet is prepared from the following raw materials in percentage by weight: 5- 20% of merariveron, 10-70% of a skeleton material, 1- 5% of an antioxidant, 0.1-5% of a lubricant, 0-70% of a filler and a proper amount of an adhesive. The merariveron sustained-release tablet adopts a film coating, and thus the stability of the merariveron sustained-release tablet is improved. The sustained-release materials in the merariveron sustained-release tablet reduce influences, on release, of different PH valves. The influences, on the absorption of the merariveron sustained-release tablet, of food, are reduced, long-time stable effective drug concentration is kept, and thus the curative effect of the merariveron sustained-release tablet is improved. A patient only needs to take the merariveron sustained-release tablet once a day; the compliance of the patient is improved.

The present invention relates to an anticancer medicine composition and belongs to the field of medicine technology. The anticancer medicine composition contains topomerase inhibitor and medicinal supplementary material. The topomerase inhibitorcan inhibit intracellular DNA repair function and reduce the tolerance one tumor cell on anticancer nitrosourea medicine; and the medicine supplementary material is mainly degradable biocompatible polymer. During the degrading and absorption process of the supplementary material, the anticancer medicine is released slowly to the tumor part, and this can lower the systemic toxic reaction while maintaining local effective medicine concentration. The anticancer medicine composition contains also anticancer nitrosourea medicine, and is set to the tumor part locally to enhance the treatment effect.

The invention discloses guanidine hydrochloride sustained release preparation and a preparation method thereof. The guanidine hydrochloride sustained release preparation is mainly prepared by guanidine hydrochloride, a filling agent, sustained release materials and potential of hydrogen (pH) sensitive materials. The preparation method comprises the steps of firstly preparing all raw materials according to proportion, evenly mixing the guanidine hydrochloride, the filling agent, the sustained release materials and the pH sensitive materials at high speed, granulating and drying the evenly mixed powder, finally adding a flow agent, a lubrication agent and an adhesion agent, tableting according to a general method, and achieving guanidine hydrochloride sustained release tablets. The guanidine hydrochloride sustained release preparation is small in side effect, obviously reduces difference of preparation of different batches, improves stability of samples, is convenient long term curing of patients and improves compliance of medicine. A patient can take the guanidine hydrochloride sustained release tablets once a day, so that effective drug concentration in bodies can be guaranteed for 24 hours, and nervous centralis side reactions caused by the fact that a blood concentration peak value is high due to general preparation is reduced.

Disclosed is a pharmaceutical composition for solid tumour which comprises anticancer available composition and medicinal adjuvant, the anticancer available composition is platinum compounds, and the medicinal adjuvant mainly employs biological compactable, degradable and absorbable macromolecular polymer. The composition can lower down the whole body toxicity reaction of the medicament when locally dispensing on the tumor, selectively increase the tumor local medicinal concentration, and improve the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation.

The present invention is solid tumor treating medicine composition and belongs to the field of medicine technology. The medicine composition contains melphalan in effective anticancer amount and medicinal supplementary material. The medicinal supplementary material is mainly biocompatible, degradable and absorbable polymer, and during the degradation and absorption of the polymer, melphalan is released slowly to local tumor part to lower the systemic toxic reaction and to maintain local medicine concentration. The present invention has enhanced treating effect. The solid tumor includes cerebral tumor, liver cancer, lung cancer, esophagus cancer, gastric cancer, etc.

An eyedrops able to become gel after it is dropped in eye for treating bacterial conjuctivities, keratitis, keratohelcosis, dacryocystitis, etc is prepared from antibacterial infilammatino-relieving medicine, thickening agent, antiseptic, isotonic regulator, pH regulator and water. Its advantages are long stay time in eye, high curative effect, and low poison and irritation.

An anticancer pharmaceutical composition composed of pharmaceutic adjuvant and anti-metabolism medicine is disclosed. Wherein, the anti-metabolism medicine can effectively destroy DNA and/or protein synthesis and repairing function inside the tumor cell so as to inhibit the tumor cell growth, while the pharmaceutic adjuvant can mainly be biological compatible, degradable and absorbable macromolecule polymer, which can make the anti-metabolism drug to release slowly in the local tumor region in the degradation and absorption process, therefore it can both decrease considerably the whole body toxic reaction and sustain the local tumor effective drug level.

The present invention relates to medicine technology and is especially new use of baicalein, which is one kind of effective components extracted from skullcap root and has been used in treating various kinds of inflammation, as antifungal medicine synergist. Baicalein is added into antifungal pyrrole medicine in the added amount of 4-16 mcg/ml. Experiments show that adding baicalein into antifungal medicine of fluconazole, ketocanazole, miconazole, etc can ensure the treating effect on fungal inflection and resist the drug tolerance of drug resisting fungi, so that baicalein may be used as the synergist of antifungal medicine.

The invention discloses a GDNF-carrying microbubble preparation and a method for making the same. The GDNF-carrying microbubble is composed of a lipid bilayer internally wrapping biological inert gas and biotinylated GDNF connected to the outside of the lipid bilayer. Employing MRI real-time guided low-frequency focused ultrasound combined with BBB opening by the GDNF-carrying microbubble to irradiate a craniocerebral parietal cortex area of a rat (the optimal parameters are set to be: probe frequency 1 Hz, microbubble 0.5 mL, irradiation period 60 s, sound pressure 0.8 MPa, and time-delay 60s) can promote GDNF to penetrate the BBB and increase the effective drug concentration of GDNF in the central nervous system. The pharmacological research after effective macromolecule breaking through of BBB by low-frequency focused ultrasound combined with target microbubble technique will further increase the advantage of neurotrophic factors in treatment of brain diseases and provide the scientific evidence for GDNF to treat nervous centralis diseases.

The present invention relates to a slow-released preparation containing beta-lactamase inhibitor. Said slow-released preparation can be made into antibiotic slow-released injection or slow-released implant preparation. Said injection is formed from slow-released microsphere and solvent, said slow-released microsphere contains slow-released auxiliary material and beta-lactamase inhibitor with antibacterial effective dose and penicillin antibiotics, the solvent is special solvent containing suspension adjuvant of carboxymethyl cellulose sodium, etc. its viscosity is 100 cp-3000 cp (20 deg.C-30deg.C); the slow-released auxiliary material is selected from EVAc, polylactic acid copolymer, sebacic acid copolymer, albumin glue and glatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application range and can obtain obvious therapeutic effect for curing various infective diseases.

The present invention relates to a slow-released preparation containing macrolide antibiotics. Said slow-released preparation is slow-released injection or slow-released implant preparation. Said injection is composed of slow-released microsphere and solvent, said slow-released microsphere contains slow-released auxiliary material and macrolide antibiotics, the solvent is special solvent containing suspension adjuvant of carboxymethyl cellulose sodium, its viscosity is 100 cp-3000 cp (20 deg.C-30 deg.C); the slow-released auxiliary material is selected from EVAc, PLA, PLGA, sebacic acid copolymer, albumin glue and golatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application method, and can obtain obvious therapeutic effect for curing various infective diseases.